Biotechnology

Pinnacle Food Group Limited Completes First Bench-Scale Fermentation of Recombinant Human Lactoferrin (rhLF) Using Methanol-Free Pichia Fermentation

October 13, 2026 8:15 AM

Pinnacle Food Group Limited (NASDAQ:PFAI) ("Pinnacle Food" or the "Company"), a technology-driven company operating at the intersection of smart farming and bioengineering, today announced that its wholly owned subsidiary, Pinnacle Food AgTech HK Limited ("PFHK"), has successfully completed the first bench-scale fermentation of the Company's first-generation recombinant human lactoferrin ("rhLF") yeast strain in a 5-liter bench-scale fermenter....

Read more

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

October 13, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM, a new application layer designed to bring its patent-pending MINT-AD Alzheimer's AI platform closer to real-world healthcare applications, including early Alzheimer's risk stratification,...

Read more

Vicore Pharma to Participate in the Chardan Healthcare Conference

October 13, 2026 2:20 AM

Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcare Conference. Location: Lotte New York Palace, New York Format: Panel discussion and 1×1 meetings Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation Date...

Read more

Senator Roger Marshall Visits Cal-Maine Foods Facility to Highlight Biosecurity and U.S. Egg Supply Resilience

October 12, 2026 12:55 PM

U.S. Senator Roger Marshall, M.D., recently visited the Cal-Maine Foods facility in Chase, Kan. to learn firsthand how the company takes a layered approach to biosecurity and food safety, which includes Synexis DHP® technology for proactive, continuous pathogen control. Senator Marshall's visit followed his recent tour of Synexis headquarters and provided an opportunity to see DHP technology deployed in an egg production environment, a method of...

Read more

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

October 12, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists who visited the Company's booth at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held October 8-10, 2026, in Porto, Portugal. The...

Read more

BioInvent International AB Announces that its CFO will Retire in 2027

October 12, 2026 4:00 AM

BioInvent International AB ("BioInvent") (STO:BINV) , a leader in the discovery of novel immunomodulatory antibodies, today announced that the company's CFO, Stefan Ericsson, has decided to retire when he turns 64 in January 2027. The process of appointing a successor will begin immediately. "On behalf of everyone at BioInvent, I would like to extend our sincere thanks to Stefan for nearly 30 years of outstanding service. He has been a pillar of...

Read more

Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City

October 9, 2026 4:05 PM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that Ehud Geller, Chief Executive Officer and Executive Chairman, will present at the 2026 ThinkEquity Conference on Thursday, October 15, 2026. Dr. Geller will be joined by Ori Gon, Chief Financial Officer, and both will be available for one-on-one meetings with investors....

Read more

Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth

October 8, 2026 8:00 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its intention to strengthen its capital markets presence through independent market-making services, a significant expansion of investor relations and public relations activities, and the addition of an experienced...

Read more

RMTG's ISSCA Division Expands Global Online Academy With Ten New Curriculum Tracks

October 8, 2026 7:02 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the next generation of its ISSCA division's Online Academy, adding ten new curriculum tracks covering biologics, exosomes, mesenchymal stromal/stem cells (MSCs), Natural Killer cells, dendritic cells, immunotherapy, CAR-T cell science, peptide...

Read more

Microbix Making Keynote Presentation at Masters Summit 2026

October 8, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to its life sciences clients and peers at the Masters Summit 2026, organized by leading eQMS provider MasterControl, Inc. and being hosted at the Hyatt Regency in Salt Lake City, Utah on October 12-15, 2026. Microbix's Manager of IT, Dmytro Panchenko, and QC Project Lead Semiramida (Nina)...

Read more

Faron Pharmaceuticals Ltd: Reminder for Investors, Analysts and Media to Register for Upcoming R&D Day

October 8, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that harness the power of the immune system, today reminds investors, analysts and media that its R&D Day will take place today on Thursday, 8 October 2026. The event will be held as a live webcast beginning at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) and is expected to last...

Read more

EicOsis Announces Alzheimer’s Association Part the Cloud Award Supporting Phase 1b Study of EC5026 in Alzheimer's Disease

October 6, 2026 2:05 PM

EicOsis Human Health, a clinical-stage biotechnology company developing novel therapies targeting soluble epoxide hydrolase (sEH) for neuroinflammatory diseases, today announced that Dr. Walter Swardfager, Associate Professor at the University of Toronto and Scientist at Sunnybrook Research Institute in Toronto, Canada, has received a $1 million award from the Alzheimer's Association's Part the Cloud program to conduct a Phase 1b...

Read more

Microbix Presenting at Cantech Investment Conference

October 6, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Cantech Investment Conference, organized by Cantech Media and being hosted at the Arcadian Loft, 8th Floor, 401 Bay Street, Toronto, Ontario on October 8, 2026. Microbix's CEO, Cameron Groome, will present and undertake a series of one-on-one meetings with growth company...

Read more

Biovica Announces Change in Pharma Services Leadership as it Strengthens its Pharma Offering

October 6, 2026 6:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica International AB announces that Henrik Winther has resigned from the company to pursue other opportunities. Henrik will remain with Biovica during notice period of six months to support an orderly transition. Pharma Services is Biovica's first priority and the fastest-growing part of the business. Henrik's departure gives the company an opportunity to further strengthen its...

Read more

Composition of Faron Pharmaceutical's Shareholders' Nomination Board

October 6, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that the following members have been re-elected by a meeting of the Company's five largest shareholders to Faron Pharmaceuticals Ltd's Shareholders' Nomination Board: Timo Syrjälä, representing himself (Chair) Erkka Kohonen,...

Read more

Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry

October 5, 2026 4:10 PM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms,...

Read more

PREMS Biomedical AI Advances AI-Enhanced Smart Sleeve for Neuromuscular Rehabilitation

October 5, 2026 8:16 AM

PREMS Biomedical AI LLC has designed an AI-enhanced wearable rehabilitation platform designed to sense a user's muscle activity and respond with proportional electrical stimulation in real time. Built around the concept of "amplifying neural effort," the PREMS smart sleeve combines surface electromyography (sEMG) sensing, electrical muscle stimulation and AI-based adaptive control. The system is being designed for home-based daily use with...

Read more

FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma

October 5, 2026 7:55 AM

FluoGuide A/S (STO:FLUO) - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotechnology company focused on precision cancer surgery, today announced that the first patient has been enrolled in FG001-CT-006, the Company's U.S. Phase 2 clinical trial of FG001 in patients with newly diagnosed high-grade glioma. Enrollment of the first patient marks the initiation of FluoGuide's first clinical trial conducted under FluoGuide's U.S....

Read more

RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies

October 5, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced a new Longevity and Adjunctive Therapies Certification from its ISSCA division. The program is focused on complementary and adjunctive technologies increasingly discussed in longevity and regenerative medicine practices. The curriculum addresses...

Read more

Bora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health Products

October 4, 2026 8:00 PM

Bora Biologics, a U.S.-anchored biologics contract development and manufacturing organization (CDMO) built for licensed supply, and Protect Animal Health, an animal health biotechnology company advancing antibody-based solutions for veterinary medicine, today announced a long-term, multi-project collaboration to support the development and manufacturing of Protect's animal health product pipeline. Under the collaboration, Protect Animal Health...

Read more